Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Fig. 3

Dapagliflozin could restore the expression of KLF-5 which was downregulated in high glucose. (A) Dapagliflozin could restore the expression of KLF-5 which was inhibited in high glucose. (B) Pearson correlation analysis showed the expression of KLF-5 and ABCA1 exhibited high correlation. (C) IF showed that the downregulation of KLF-5 in high glucose could be upregulated significantly by dapagliflozin treatment. (Data presented are the mean ± S.D.; *P < 0.05 vs. LG, # P < 0.05 vs. HG, n = 3)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us